Newsbenzinga
Roivant Says Brepocitinib Met Primary, All Key Secondary Endpoints In Two Phase 3 Non-Infectious Uveitis Trials; Plans sNDA In H1 2027
· Published
Article summary
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…